Delving into the Latest Updates on ABT-288 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

H3 receptor

Mechanism

H3 receptor antagonists(Histamine H3 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [2]

Active Indication-

Inactive Indication

Alzheimer DiseaseChanarin-Dorfman SyndromeCognitive Dysfunction+ [1]

Originator Organization

AbbVie, Inc.

Active Organization-

Inactive Organization

AbbVie, Inc.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC23H24N4O

InChIKeyGNIRITULTPTAQW-KNQAVFIVSA-N

CAS Registry948845-91-8

BACKGROUNDNo comprehensive meta-analysis has been performed concerning the efficacy and tolerability of histamine H3 receptor antagonists (H3R-ANTs) in Alzheimer's disease patients.OBJECTIVEWe performed a systematic review and meta-analysis of double-blind randomized placebo-controlled trials (RCTs) of H3R-ANTs for Alzheimer's disease.METHODSRelevant studies were identified through searches of PubMed, databases of the Cochrane Library, and PsycINFO citations up to June 19, 2015. The primary outcome was a change in the Mini-Mental State Examination (MMSE) scores. Secondary outcomes were Neuropsychiatric Inventory (NPI) scores, discontinuation rate, and individual adverse events/side effects. Risk ratios, numbers-needed-to-treat/harm, and standardized mean differences were calculated based on a random effects model.RESULTSThe computerized search initially yielded 33 studies after excluding duplicates. We excluded 29 of these articles following a review of titles and abstracts and one RCT including healthy subjects after full-text review. We identified three RCTs (two on GSK239512 and one on ABT-288) including 402 patients. Pooled H3R-ANTs were not superior to placebo for improvement in MMSE and NPI scores. Discontinuation rate and individual adverse events/side effects did not differ among the pooled groups.CONCLUSIONSOur results suggest that H3R-ANTs are not effective in treating cognitive dysfunction in Alzheimer's disease. However, further studies with larger samples are required for definitive conclusions regarding responsive subpopulations.

01 Nov 2014·Schizophrenia BulletinQ1 · MEDICINE

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Q1 · MEDICINE

Article

Author: Robieson, Weining ; Othman, Ahmed A ; Baker, Jeffrey ; Bain, Earle ; Haig, George M ; Lenz, Robert A

INTRODUCTIONABT-288 is a highly potent histamine-3 receptor antagonist that has demonstrated pro-cognitive effects in preclinical models relevant to schizophrenia. This study evaluated the efficacy and safety of two doses of ABT-288 in the treatment of cognitive impairment associated with schizophrenia.METHODSA randomized, double-blind, placebo-controlled, parallel-group 12-week study was conducted at 23 centers in the United States. Clinically stable subjects with schizophrenia were randomized in an equal ratio to ABT-288 10 mg, ABT-288 25 mg, or placebo once daily while continuing their antipsychotic regimen. The primary efficacy measure was the change from baseline to day 84 evaluation on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) composite score vs placebo. Secondary measures included cognitive functioning and psychiatric scales. Safety assessments and sparse pharmacokinetic sampling were also conducted.RESULTSA total of 214 subjects were randomized. The mean baseline MCCB composite score was 28.4. Approximately 80% of subjects completed the study. The MCCB composite score mean change from baseline to day 84 was numerically worse for both the 10 mg (1.90, P = .618) and 25 mg (0.64, P = .946) doses of ABT-288 vs placebo (2.19). Results from the secondary measures were consistent with the primary analysis. Subjects' schizophrenia symptoms remained stable throughout the study as evidenced by stable Positive and Negative Syndrome Scale scores. Overall, study medication was tolerated; however, an increased incidence of psychosis-related and sleep-related adverse events was associated with ABT-288.DISCUSSIONNeither dose of ABT-288 resulted in cognitive improvement in clinically stable adults with schizophrenia.

16 Sep 2014·Journal of Alzheimer's DiseaseQ3 · MEDICINE

A Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1

Q3 · MEDICINE

Article

Author: Haig, George M. ; Othman, Ahmed A. ; Gault, Laura M. ; Hall, Coleen ; Meier, Andreas ; Lenz, Robert A. ; Pritchett, Yili

BACKGROUNDABT-288, a highly selective histamine-3 receptor antagonist, demonstrated efficacy across several preclinical cognitive domains, and safety in healthy subjects and elderly volunteers.OBJECTIVEEvaluate the efficacy and safety of ABT-288 in subjects with mild-to-moderate Alzheimer's dementia.METHODSThe study used a randomized, double-blind, placebo- and active-controlled, parallel group design with pre-defined futility criteria to permit early study termination. A total of 242 subjects were randomized in an equal ratio to ABT-288 1 mg or 3 mg, donepezil 10 mg, or placebo once daily for 12 weeks. The primary efficacy endpoint was the change from baseline to final evaluation on the 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score.RESULTSThe study was prematurely terminated because futility criteria were met. Point estimates on the ADAS-Cog scores for both ABT-288 dose groups were numerically inferior to placebo but no statistical differences were detected. Donepezil demonstrated statistically significant improvement. Adverse events were generally mild and self-limiting.CONCLUSIONABT-288 did not demonstrate efficacy in the symptomatic treatment of Alzheimer's dementia.

100 Deals associated with ABT-288

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15192

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chanarin-Dorfman Syndrome	Phase 2	US	AbbVie, Inc.	01 Mar 2010
Cognitive Dysfunction	Phase 2	US	AbbVie, Inc.	01 Mar 2010
Schizophrenia	Phase 2	US	AbbVie, Inc.	01 Mar 2010
Alzheimer Disease	Phase 2	UA	AbbVie, Inc.	01 Dec 2009
Alzheimer Disease	Phase 2	RU	AbbVie, Inc.	01 Dec 2009